DOSE ADJUSTMENT OF NIFEDIPINE IN HYPERTENSIVE PATIENTS

被引:7
作者
BACRACHEVA, N [1 ]
THUERMANN, P [1 ]
RIETBROCK, N [1 ]
机构
[1] UNIV FRANKFURT,DEPT CLIN PHARMACOL,W-6000 FRANKFURT 1,GERMANY
关键词
concentration-effect relationship; hypertension; individual dose; nifedipine; side effects;
D O I
10.1007/BF00314796
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ten patients with essential hypertension (WHO grade I-II) were treated in an open dose-adjustment study with the standard regimen of slow-release nifedipine 20 mg b. d. for 2 weeks and with an individualized dose for 6 weeks. The optimum dose, defined as that producing a pre-dose diastolic blood pressure (dBP) of 90 mm Hg at steady state, was determined from the individual concentration-effect relationship after a test-dose of 20 mg. On standard therapy, the reduction in pre-dose dBP was inadequate in 4 patients and it was excessive in 1 patient. After 2 weeks of individualized treatment, the required pre-dose antihypertensive effect was obtained in all patients. The individual doses required were 10 mg b. d., 10 mg t. d. s. 20 mg b. d., 20 mg t. d. s. and 20 mg q. d. s. One patient dropped out of the study because of side effects. Loss of the antihypertensive effect was observed in one patient after 6 weeks of treatment. On the optimized dose, the average value of the pre-and 2 h post-dose steady state nifedipine concentrations (27.6 μg/l) compared well with model-derived optimum concentrations (28.6 μl/l) (r=0.9210). The results show that the dose of nifedipine can be accurately predicted using the individual concentration-effect relationship after a single dose. © 1990 Springer-Verlag.
引用
收藏
页码:17 / 20
页数:4
相关论文
共 17 条
[1]   STANDARDIZATION OF SYMBOLS IN CLINICAL-PHARMACOLOGY [J].
ARONSON, JK ;
DENGLER, HJ ;
DETTLI, L ;
FOLLATH, F .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 35 (01) :1-7
[2]   EVALUATION OF THE EFFICACY OF SLOW-RELEASE NIFEDIPINE IN SYSTEMIC HYPERTENSION BY AMBULATORY INTRAARTERIAL BLOOD-PRESSURE MONITORING [J].
BONADUCE, D ;
CANONICO, V ;
MAZZA, F ;
NICOLINO, A ;
FERRARA, N ;
CHIARIELLO, M ;
CONDORELLI, M .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1985, 7 (01) :145-151
[3]   NIFEDIPINE - INDIVIDUAL-RESPONSES AND CONCENTRATION-EFFECT RELATIONSHIPS [J].
DONNELLY, R ;
ELLIOTT, HL ;
MEREDITH, PA ;
KELMAN, AW ;
REID, JL .
HYPERTENSION, 1988, 12 (04) :443-449
[4]   UNDERSTANDING THE DOSE-EFFECT RELATIONSHIP - CLINICAL-APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELS [J].
HOLFORD, NHG ;
SHEINER, LB .
CLINICAL PHARMACOKINETICS, 1981, 6 (06) :429-453
[5]   NIFEDIPINE TABLETS FOR SYSTEMIC HYPERTENSION - A STUDY USING CONTINUOUS AMBULATORY INTRAARTERIAL RECORDING [J].
HORNUNG, RS ;
GOULD, BA ;
JONES, RI ;
SONECHA, TN ;
RAFTERY, EB .
AMERICAN JOURNAL OF CARDIOLOGY, 1983, 51 (08) :1323-1327
[6]  
KLEINBLOESEM C, 1984, CLIN PHARMACOL THER, V36, P742
[7]   PHARMACOKINETICS AND HEMODYNAMIC-EFFECTS OF LONG-TERM NIFEDIPINE TREATMENT IN HYPERTENSIVE PATIENTS [J].
KLEINBLOESEM, CH ;
VANBRUMMELEN, P ;
FABER, H ;
BREIMER, DD .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1987, 9 (02) :202-208
[8]   RATE OF INCREASE IN THE PLASMA-CONCENTRATION OF NIFEDIPINE AS A MAJOR DETERMINANT OF ITS HEMODYNAMIC-EFFECTS IN HUMANS [J].
KLEINBLOESEM, CH ;
VANBRUMMELEN, P ;
DANHOF, M ;
FABER, H ;
URQUHART, J ;
BREIMER, DD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (01) :26-30
[9]  
KURODA T, 1985, Kobe Journal of Medical Sciences, V31, P133